Nanoparticles, anti-inflammatory agents, and reactive oxygen species scavengers

Nanoparticles with crosslinked biocompatible polymers and polyethyleneimine derivatives provide targeted delivery to inflamed areas, enhancing therapeutic efficacy and safety by accumulating in specific regions like the large intestine.

JP7873470B2Active Publication Date: 2026-06-12NAT INST FOR MATERIALS SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022013831
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-02-01
Publication Date
2026-06-12
Estimated Expiration
2042-02-01

AI Technical Summary

Technical Problem

Existing anti-inflammatory agents and ROS scavengers face challenges in safely and effectively delivering to inflamed areas, such as the large intestine, leading to insufficient therapeutic efficacy and systemic side effects.

Method used

Nanoparticles composed of crosslinked biocompatible polymers, such as hyaluronic acid or derivatives, crosslinked with polyethyleneimine or its derivatives, with specific molecular weights and amino group contents, designed to have a negative zeta potential and a particle size of 100-1000 nm, allowing targeted delivery to inflamed areas.

Benefits of technology

The nanoparticles efficiently accumulate in inflamed regions, exhibiting high therapeutic efficacy with reduced systemic side effects and enhanced safety, making them suitable for oral administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007873470000006
    Figure 0007873470000006
  • Figure 0007873470000007
    Figure 0007873470000007
  • Figure 0007873470000008
    Figure 0007873470000008
Patent Text Reader

Abstract

To provide a nanoparticle that has safety and anti-inflammatory action and is also efficiently delivered, when orally administered, to an affected inflammatory area, exhibiting a high therapeutic effect.SOLUTION: A nanoparticle includes a biocompatible polymer crosslinked with polyethyleneimine or polyethyleneimine derivatives with weight average molecular weight of 100-1000. The crosslinked biocompatible polymer includes a primary amino group.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Proinflammatory cytokine production inhibitor, hyaluronic acid derivative, and method for producing hyaluronic acid derivative

    JP2021031453A

  • Anti-inflammatory agent, prefilled syringe, and kit

    JP2021031454A